Unnatural Products

Unnatural Products (UNP) specializes in developing new drugs through a platform that combines AI with chemistry. The company focuses on engineering synthetic macrocycles, a type of large, ring-shaped molecule, to mimic natural macrocycles. These macrocycles can target complex proteins that are difficult to address with traditional small molecules or biologics, potentially offering new treatments for various diseases.

The company plans to build a pipeline of compounds with a focus on identifying cancer treatments initially.

Key customers and partnerships

In October 2021 , UNP partnered with BridgeBio Pharma to generate drug-like macrocycles to target rare fibrotic diseases and potential oncology applications. In January 2024 , it partnered with Merck and Co. to collaboratively develop a cancer therapy in a deal amounting to USD 220 million.

Funding and financials

In December 2023 , UNP raised USD 32 million in a Series A funding round led by Merck Global Health Innovation Fund and ARTIS Ventures. New investors including First Spark Ventures, The Venture Collective, Humain Ventures, LongeVC, and Not Boring Capital, alongside existing investors, also participated in the round. The funds were allocated toward advancing UNP’s technology platform and expanding to other therapeutic opportunities.